This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

LJP 1082

La Jolla Pharmaceutical Company

Drug Names(s): LJP 1082

Description: LJP 1082 is a tetravalent conjugate of recombinant human domain 1 that has been shown to reduce domain 1 specific antibodies and levels of antigen-specific antibody producing B cells in rodents.

Deal Structure: LJP 1082 was originally developed by La Jolla Pharmaceutical Company.

In December 2009, Adamis Pharmaceuticals announced that it has entered into a definitive merger agreement providing for the acquisition of La Jolla Pharmaceutical Company by Adamis. The transaction was unanimously approved by the boards of directors of both companies and is anticipated to close by the end of the first calendar quarter of 2010.

In March 2010, Adamis Pharmaceuticals announced that Adamis and La Jolla Pharmaceutical Company agreed to terminate their merger agreement relating to the proposed merger of the two companies.

LJP 1082 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug